Hosted on MSN9mon
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung CancerOn Friday, Pfizer Inc (NYSE:PFE) released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) available in Europe as Lorviqua versus Xalkori (crizotinib ...
Pfizer’s ALK inhibitor Xalkori is facing a further challenge from Takeda newcomer Alunbrig, which outperformed it in a phase 3 trial. Takeda has reported updated results from its ALTA-1L trial ...
Pfizer’s Xalkori is already approved to treat patients with ROS1 mutations (alongside its use in ALK+ patients), but Ignyta’s drug looks likely to be superior, thanks in part to its ability to ...
An expert explained the importance of the FDA’s approval of Ensacove for patients with ALK-positive non-small cell lung ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results